Inline Q4 ensured a healthy finish to FY 25
25/02/26 -"Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported by accelerating biosimilars adoption and expanding ..."
Pages
55
Language
English
Published on
25/02/26
You may also be interested by these reports :
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...
23/02/26
Considering the lower medium-to-long-term expectations, the premium for peer-based metrics has been reduced to 25% (vs. 50% previously). However, ...